General contact information for trials in the Maritimes:

Nova Scotia:

Current trials:


Recruiting location in the Maritimes:

  • Halifax – QEII Health Science Centre (Dr. Kirk Magee:

ID Number: NCT02743494


Description: This study looks at the drug nivolumab for patients with advanced gastric cancer who have had surgery. The experiment will compare the survival of two patient groups after surgery:

  • Group A will receive Nivolumab.
  • Group B will receive a placebo instead.  

Intervention: Sometimes, cancer cells stop our immune system from recognizing the growth of a tumor.  This way, the cancer is effectively able to “hide” from our body’s immune defense mechanisms. Nivolumab is a drug which helps your immune system (T cells) find and attack cancerous cells. This means that it is a type of immunotherapy drug.

Can I consider participating?

  • Yes: patients who already had chemoradiotherapy and surgery for stage 2 or 3 esophageal or gastroesophageal cancer, however the disease is still present
  • No: patients who have stage 4 cancer, or did not have chemoradiotherapy before surgery


Recruiting location in the Maritimes:

  • Halifax – QEII Health Sciences Centre (Erin Little: 902-473-3735)

ID Number: NCT02935634


Description: This is a Phase III pilot trial. The participants in this study will be patients with Gastroesophageal Junction adenocarcinoma. The researchers want to know if perioperative chemotherapy or preoperative chemoradiotherapy is more helpful. This is a pilot study, which means that it is quite small and the researchers are trying to figure out if it is feasible to conduct a larger trial to answer their question with more data. They will compare the survival of two groups to try and find a better treatment for Gastroesophageal Junction cancer:

  • Group 1: the perioperative chemotherapy group will receive 1 of 2 possible chemotherapy routines: epirubicin/cisplatin/fluorouracil (ECF) or fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT). The chemotherapy is given before and after surgery.
  • Group 2: the preoperative group will receive chemotherapy and radiation therapy before surgery only. The drugs they will receive are carboplatin and paclitaxel.


  • Carboplatin and paclitaxel work to stop cancer cells from dividing. In this trial, they are given along with radiation therapy to treat the cancer.
  • The ECF and FLOT chemotherapy routines both work to try and stop cancer cells from dividing properly. Both are already prescribed commonly in gastric/gastroesophageal cancer treatment.

Can I consider participating?

  • YES: tumor of the esophagus or gastroesophageal junction which does not extend too far into the stomach itself (no more than 2 cm), aged 18-75, tumor is less than 8 cm in length and 5 cm in diameter
  • NO: have already tried chemotherapy or radiation therapy for esophageal/gastroesophageal cancer, had a malignant cancer within the last 5 years